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Sir
Drs Ulrich and Potter appear to have missed the point of our
study on the predictive value of the polymorphism in the thymi-
dylate synthase (TS) promoter (Iacopetta et al, 2001). The aim
was to determine whether this genotype was associated with the
degree of survival beneﬁt gained from the use of adjuvant, 5-
ﬂuorouracil-based (5FU) chemotherapy in colorectal cancer
patients. To achieve this aim, we compared the survival of
patients treated by surgery alone to those treated by surgery
and chemotherapy. There was a clear long-term survival beneﬁt
for the combined 2R/2R and 2R/3R patient group, but not for
the 3R/3R group. We agree however that the predictive value of
the 3R/3R genotype is weak and, as stated in the Discussion of
our article direct biochemical or immunohistochemical evaluation
of TS level is likely to be required for clinical applications relating
to patient selection for 5FU chemotherapy. Investigation of the
prognostic value of TS genotypes within the chemotherapy group,
as suggested by Ulrich and Potter, was not our primary aim. As
shown in the Results of our article, the survival of 3R/3R patients
in this group was marginally worse than that of 2R/2R or 2R/3R
patients, presumably because they gained less survival beneﬁt from
the adjuvant treatment.
It is interesting to note that during the publication of our
manuscript there have been two other reports on the predictive
value of TS genotype. The ﬁrst by Villafranca et al (2001) showed
that rectal tumours from patients with the 3R/3R genotype showed
a lower probability of down-staging after pre-operative chemo-
(5FU)-radiation treatment compared to 2R/2R or 2R/3R genotypes
(22% vs 60%, respectively). The second by Pullarkat et al (2001)
showed that metastatic colorectal cancer patients with the 3R/3R
genotype had a lower response rate (9%) to treatment with 5FU
compared to those with the 2R/2R genotype (50%). Both ﬁndings
are in agreement with our observations of less survival beneﬁt from
5FU treatment for 3R/3R genotype patients compared to those
with 2R/2R or 2R/3R genotypes.
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